Keynote Speakers
CARO ASM 2022 Keynote Speakers
Dr. David Palma, MD, PhD is a Professor and Radiation Oncologist at Western University in London, Ontario, Canada. He earned his MD at the University of Western Ontario and completed his radiation oncology residency at the BC Cancer Agency in Vancouver. He holds Master’s Degree in Epidemiology from the Harvard School of Public Health and a PhD from the VU University in Amsterdam. He has led several international randomized trials in radiation oncology, and he is the chair of the Canadian Pulmonary Radiotherapy Investigators (CAPRI) group. He is the author of the bestselling book Taking Charge of Cancer: What You Need to Know to Get the Best Treatment.
Dr. Mark Corkum is a radiation oncologist with interests in genitourinary malignancies, brachytherapy, oligometastases and population-based data. He completed his residency at Western University in 2020 and his fellowship in GU brachytherapy (Area of Focused Competence) at the Sunnybrook Odette Cancer Centre in 2021.
Dr. Keyes is a Clinical Professor in Radiation Oncology, University of British Columbia (UBC), a Fellow (FABS) of American Brachytherapy Society (ABS), ABS board member, recipient of ABS President Award and a Vice-Chair of the Royal College of Physicians and Surgeons of Canada AFC (Area of Focused Competence) Diploma in Brachytherapy. She is an AFC program director at UBC, former UBC Radiation Oncology Residency Training Program director and recipient of several teaching and mentorship awards. She is a CARO and BC Cancer wellness committee chair. Dr. Keyes is a keynote speaker at international conferences an author of over 100 peer-reviewed manuscripts. She holds CIHR and Michael Smith Foundation grant for translational research in prostate cancer.
Dr. Sue S. Yom, MD, PhD, MAS, FASTRO, FAAWR, FACR is the Vice Chair of Strategic Advisory and the Irwin Mark Jacobs and Joan Klein Jacobs Distinguished Professor in the Departments of Radiation Oncology and Otolaryngology – Head and Neck Surgery at the University of California San Francisco. She is Editor-in-Chief of the International Journal of Radiation Oncology Biology Physics, Chair of the NRG Oncology Head and Neck Cancer Committee, and Board Member and Guidelines and Protocols Committee Co-Chair for the Head and Neck Cancer International Group. She is Immediate Past President of the American Radium Society. She is a member of the NCCN Head and Neck Cancers guidelines committee and the Head and Neck Cancer Resource Panel, Education, and Science Education Committees of the American Society of Radiation Oncology. At UCSF, she serves as Co-Chair of the Oral, Head and Neck Site Committee, Contact PI for NRG Oncology, and Full Member in Molecular Oncology within the Helen Diller Family Comprehensive Cancer Center. She has been author or co-author on over 200 publications in the medical literature. She serves on organizing committees for numerous radiation oncology and head and neck and lung cancer professional societies.
Theme Symposium Speakers
Cynthia Ménard received her M.D. degree from the University of Calgary in 1996, and completed her residency in Radiation Oncology at the University of Alberta, Edmonton, in 2001. She was a research fellow in the Radiation Oncology Branch of the National Cancer Institute (NCI) until 2003, where she subsequently worked as Staff Clinician until 2004. She then returned to Canada as an Associate Professor and Clinician Scientist in the Radiation Medicine Program at Princess Margaret Cancer Centre, University of Toronto until 2015.
She now pursues her research as a Radiation Oncologist at CHUM (Centre de Recherche du Centre Hospitalier de l’Université de Montréal), and as a Professor at University of Montréal. Her research program continues to focus on translational research in the development, validation, and clinical application of novel imaging techniques to radiotherapy.
Dr. Giambattista is currently in practice at the Allan Blair Cancer Centre (Regina, SK) treating patients with head and neck, thyroid, breast and CNS malignancies. Dr. Giambattista completed medical school at the University of Saskatchewan followed by medical residency in Radiation Oncology at University of British Columbia (BC Cancer Agency).
Dr. Giambattista’s research activity includes projects related to validation and prospective evaluation of AI auto-segmentation models. Dr. Giambattista is a co-founder of Limbus AI and remains involved in a clinical advisory role focused on dataset and contour quality management and assists with collaborative clinical research projects between Limbus AI and academic centres across North America and Europe.
Dr. Michael Velec is a Radiation Therapist–Clinician Scientist and the MR-Guided Radiotherapy Program Leader in the Radiation Medicine Program, Princess Margaret Cancer Centre. Michael completed his PhD in medical sciences at the University of Toronto in 2014, and a postdoctoral fellowship in medical physics at the Techna Institute in 2016. He is an Assistant Professor in Radiation Oncology at the University of Toronto and researcher within the Princess Margaret Research Institute. Dr. Velec’s research spans ‘high tech/high touch’ projects that include adaptive radiation therapy and radiation therapist practices that enable person-centered care.
CARO-ESTRO Speaker
Dr. Srinivas Raman is a staff radiation oncologist at the Princess Margaret Cancer Centre and an assistant professor in the department of radiation oncology, University of Toronto. Srinivas previously completed a bachelor’s and master’s degree in mechanical engineering, and medical school at University of British Columbia, followed by radiation oncology residency at University of Toronto. He received the 2018 CARO fellowship award to study knowledge-based methods for radiotherapy quality assurance in clinical trials, and undertook a clinical-research fellowship at BC Cancer Vancouver. His research interests are centered in applying automation and artificial intelligence in clinical workflows to improve patient care.
Dr. Marco van Vulpen (MD, PhD) is radiation oncologist and the medical director of Holland Proton Therapy Center (HollandPTC) in Delft, the Netherlands. He is also appointed as full professor at Leiden University Medical Center (LUMC), and at Erasmus University Medical Center (Erasmus MC) in Rotterdam and at the Technical University of Delft, faculty of applied sciences. Furthermore, he is appointed as Medical Delta professor.
Marco van Vulpen obtained his M.D. at the University of Amsterdam and his Ph.D. (2003) at the University of Utrecht, both in the Netherlands. Since 2003 he worked as radiation oncologist at the University Medical Center Utrecht (UMCU), where he was appointed full professor in 2011. His inaugural speech was called ‘the End of Radiotherapy’ (text). From 2013 to 2017 he was chair of the department of Radiotherapy at the UMCU, where a 1.5 Tesla MRI linear accelerator was developed. From 2015 to 2017 he was member of the management team of the oncology division at the UMCU. He was clinical chair of the International Consortium, ATLANTIC, on the worldwide clinical introduction of the MRI linac. Since 2016 he works at HollandPTC as medical director with professorships in the surrounding medical and technical universities. His inaugural speech was called “Critical Mass” (text).
From 2014 to 2021 he held an adjunct position at the department of radiotherapy at the University of Texas MD Anderson Cancer Center in Houston, Texas.
Marco van Vulpen received the ‘Alon Dembo visiting professor’ award at the University of Toronto (2012) and the ‘Donal Hollywood’ award at the European Society of radiotherapy and oncology (ESTRO) (2016). He is honorary member of the Belgian society for radiotherapy (ABRO-BVRO).
His major research interests include the development, clinical translation and implementation and the value proposition off different radiotherapy interventions.
Dr. Andrew McPartlin completed his Clinical Oncology training at The Christie, Manchester, UK, where he has practiced as a Consultant specializing in HN Malignancy and Proton therapy. He joined Princess Margaret Cancer Center in 2022. His research interests include technical radiotherapy, including the use of MRI in head and neck radiotherapy.